Core Points - BioStem Technologies Inc. will release its second quarter 2025 financial results on August 14, 2025, and will host a conference call and webcast at 4:30 PM ET [3][4] - The conference call will include a review of the financial results and updates on the Company's Form 10 filing and Nasdaq uplisting, led by CEO Jason Matuszewski and CFO Michael Fortunato [4] - BioStem Technologies focuses on the development, manufacture, and commercialization of placental-derived products for advanced wound care, utilizing its proprietary BioREtain® processing method [6][7] Company Overview - BioStem Technologies is recognized as a leading innovator in the MedTech sector, specializing in allografts for advanced wound care [6] - The Company’s quality management systems are accredited by the American Association of Tissue Banks (AATB) and comply with Good Tissue Practices (cGTP) and Good Manufacturing Processes (cGMP) [7] - BioStem's product portfolio includes brands such as AmnioWrap2™, VENDAJE®, and American Amnion™, all processed at its FDA registered and AATB accredited facility in Pompano Beach, Florida [7]

Core Viewpoint - BioStem Technologies, Inc. is showcasing its innovative placental-derived products for chronic wound care at the Symposium for Advanced Wound Care (SAWC) Spring meeting, emphasizing collaboration with Venture Medical, LLC to enhance patient management and treatment outcomes [1][2][3]. Company Overview - BioStem Technologies focuses on the development, manufacturing, and commercialization of placental-derived products aimed at advanced wound care [1][13]. - The company utilizes its proprietary BioREtain processing method to preserve the natural properties of perinatal tissue, ensuring the efficacy of its allografts [11][13]. Partnership Highlights - The collaboration with Venture Medical, LLC aims to streamline the logistics of managing patients requiring skin substitutes for chronic wound treatment [2][3]. - BioStem's leading products, AmnioWrap2 and Vendaje AC, are exclusively available through Venture Medical, which has effectively penetrated the physician office and mobile segments [3]. Event Participation - BioStem will co-exhibit with Venture Medical at the SAWC Spring meeting in Dallas, TX, from April 30 to May 4, 2025, featuring three accepted scientific posters on its advanced allograft portfolio [1][6]. - The booth schedule includes discussions on reimbursement landscapes, mobile wound care practices, and the benefits of BioStem's BioREtain technology [3][8]. Scientific Contributions - Three clinical and scientific posters accepted for presentation will demonstrate favorable outcomes with BioREtain technology and comparisons with competitive products [10]. - Ongoing randomized clinical trials are evaluating the treatment of diabetic foot ulcers and venous leg ulcers, with results expected later this year [10]. Educational Initiatives - A sponsored breakfast symposium titled "Healing Under Pressure: Advancements in Skin Substitutes for Pressure Ulcer Treatment" will address the importance of comprehensive care for patients with chronic wounds [5].